Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cybin Inc. (HELP : NSDQ)

• Company Description    Helus Pharma is a clinical stage pharmaceutical company. Its lead candidate includes HLP003 and HLP004. Helus Pharma, formerly known as Cybin Inc., is based in BOSTON. Number of Employees: 100

• Price / Volume Information    Yesterday's Closing Price: $7.62 Daily Weekly Monthly 20 Day Moving Average: 1,732,754 shares Shares Outstanding: 69.87 (millions) Market Capitalization: $532.44 (millions) Beta: 0.62 52 Week High: $9.12 52 Week Low: $3.76 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 26.58% 25.65% 12 Week 43.50% 39.57% Year To Date -6.85% -12.68%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 100 KING STREET WEST SUITE 5600 - TORONTO,A6 M5X 1C9 CAN ph: 908-764-8385 fax: - ir@cybin.com http://www.cybin.com

• General Corporate Information    Officers Eric So - President and Chief Executive Officer Aaron Bartlone - Chief Operating Officer Greg Cavers - Chief Financial Officer Theresa Firestone - Director Grant Froese - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 23256X407 SIC: 2834 Fiscal Year Fiscal Year End: March Last Reported Quarter: 12/01/25 Next Expected EPS Date: 08/12/26 Share - Related Items Shares Outstanding: 69.87 Most Recent Split Date: 9.00 (0.03:1) Beta: 0.62 Market Capitalization: $532.44 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.80 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.17 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.70 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -89.47% vs. Previous Quarter: 48.20% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - -68.27 12/31/25 - -60.43 ROA 06/30/26 - - 03/31/26 - -58.26 12/31/25 - -51.15 Current Ratio 06/30/26 - - 03/31/26 - 9.52 12/31/25 - 13.78 Quick Ratio 06/30/26 - - 03/31/26 - 9.52 12/31/25 - 13.78 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - - 03/31/26 - 4.49 12/31/25 - 5.49 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©